tarextumab

01/01/2019 - "Purpose This Phase I trial evaluated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel cross-reactive antibody which binds and selectively inhibits signaling via both Notch2 and Notch3, in adult patients with advanced malignancies. "
01/01/2019 - "A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors."
01/01/2019 - "Based on preclinical and phase Ib results suggesting a positive correlation between Notch3 gene expression and tarextumab anti-tumor activity, patients were also divided into subgroups of low, intermediate, and high Notch3 gene expression. "
05/01/2015 - "In the tumor stroma, OMP-59R5 consistently inhibited the expression of Notch3, HeyL, and Rgs5, characteristic of affecting pericyte function in tumor vasculature. "
05/01/2015 - "OMP-59R5 inhibits both human and mouse Notch2 and Notch3 function and its antitumor activity was characterized by a dual mechanism of action in both tumor and stromal/vascular cells in xenograft experiments. "

01/01/2019 - "A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer."

01/01/2019 - "Grade 3 diarrhea and thrombocytopenia were more common in the tarextumab group. "

01/01/2019 - "Grade 3 diarrhea and thrombocytopenia were more common in the tarextumab group. "